Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:20:49 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:MNKD - MANNKIND CORPORATION - https://www.mannkindcorp.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MNKD - Q1.13.73·4.170.13.76-0.14-3.62,315.28,3238,0603.92  3.92  3.757.62  3.5119:58:06Jun 0915 min RT 2¢

Recent Trades - Last 10 of 8060
Time ETExPriceChangeVolume
19:58:06Q3.83-0.071
19:55:18Q3.75-0.15112
19:53:52Q3.77-0.1310
19:14:23Q3.84-0.061
19:03:49Q3.84-0.0625
18:48:44Q3.77-0.133
18:38:24Q3.8485-0.051534
18:31:43Q3.74-0.161,750
18:30:01Q3.76-0.141
18:17:53Q3.7401-0.1599100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-09 16:05U:MNKDNews ReleaseMannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza(TM)) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23
2025-05-27 09:15U:MNKDNews ReleaseINDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29
2025-05-13 16:05U:MNKDNews ReleaseMannKind to Present at Upcoming Investor Conferences
2025-05-08 08:05U:MNKDNews ReleaseMannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
2025-05-01 16:05U:MNKDNews ReleaseMannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025
2025-04-07 12:30U:MNKDNews ReleaseMannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options
2025-03-10 06:05U:MNKDNews ReleaseMannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza(TM) at the ATTD Conference, March 19-22
2025-02-26 16:05U:MNKDNews ReleaseMannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2025-02-19 16:05U:MNKDNews ReleaseMannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025
2025-02-06 16:05U:MNKDNews ReleaseMannKind to Present at Upcoming Investor Conferences
2025-01-06 16:30U:MNKDNews ReleaseMannKind Expands Executive Leadership Team
2024-12-18 07:00U:MNKDNews ReleaseMannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
2024-12-16 06:05U:MNKDNews ReleaseMannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza(TM))
2024-12-11 06:00U:MNKDNews ReleaseCDSCO Approves Afrezza(TM) (insulin human) Inhalation Powder in India
2024-11-07 16:02U:MNKDNews ReleaseMannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
2024-11-05 16:15U:MNKDNews ReleaseMannKind to Present at 2024 UBS Healthcare Conference
2024-11-04 06:05U:MNKDNews ReleaseMannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
2024-10-31 16:05U:MNKDNews ReleaseMannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
2024-09-30 06:00U:MNKDNews ReleaseMore Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza(TM))
2024-09-18 06:15U:MNKDNews ReleaseMannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease